To date, three molecular markers (ER, PR, and CYP2D6) have been used in clinical setting
to predict the benefit of the anti-estrogen tamoxifen therapy. Our aim was to validate new …

In early breast cancer (eBC), established clinicopathological factors are not sufficient for
clinical decision making particularly regarding adjuvant chemotherapy since substantial …

No gold standard treatment exists for metastatic breast cancer (MBC). Clinical decision
making is based on knowledge of prognostic and predictive factors that are extrapolated …

Background Given its high recurrence risk, guidelines recommend systemic therapy for most
patients with early-stage triple-negative breast cancer (TNBC). While some clinicopathologic …

Background: The 2010 guidelines by ASCO-CAP have mandated that breast cancer
specimens with≥ 1% positively staining cells by immunohistochemistry should be …

Around 70% of all breast cancers are estrogen receptor alpha positive and hence their
development is highly dependent on estradiol. While the invention of endocrine therapies …

Breast carcinoma (BC) has been extensively profiled by high-throughput technologies for
over a decade, and broadly speaking, these studies can be grouped into those that seek to …

Cancer treatment is undergoing a significant revolution from “one‐size‐fits‐all” cytotoxic
therapies to tailored approaches that precisely target molecular alterations. Precision …

Purpose To assess the prognostic role of different inter and intralesional expression
(heterogeneity) of oestrogen receptor (ER) in bone metastases, as identified by the …

Purpose Differences in tumor biology, genomic architecture, and health care delivery
patterns contribute to the breast cancer mortality gap between White and Black patients in …